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ABSTRACT

SARS-CoV-2 is the causative agent of COVID-19 and responsible for the current global pandemic. We and others have
previously demonstrated that cats are susceptible to SARS-CoV-2 infection and can eﬃciently transmit the virus to
naïve cats. Here, we address whether cats previously exposed to SARS-CoV-2 can be re-infected with SARS-CoV-2. In
two independent studies, SARS-CoV-2-infected cats were re-challenged with SARS-CoV-2 at 21 days post primary
challenge (DPC) and necropsies performed at 4, 7 and 14 days post-secondary challenge (DP2C). Sentinels were comingled with the re-challenged cats at 1 DP2C. Clinical signs were recorded, and nasal, oropharyngeal, and rectal
swabs, blood, and serum were collected and tissues examined for histologic lesions. Viral RNA was transiently shed
via the nasal, oropharyngeal and rectal cavities of the re-challenged cats. Viral RNA was detected in various tissues of
re-challenged cats euthanized at 4 DP2C, mainly in the upper respiratory tract and lymphoid tissues, but less
frequently and at lower levels in the lower respiratory tract when compared to primary SARS-CoV-2 challenged cats
at 4 DPC. Viral RNA and antigen detected in the respiratory tract of the primary SARS-CoV-2 infected cats at early
DPCs were absent in the re-challenged cats. Naïve sentinels co-housed with the re-challenged cats did not shed virus
or seroconvert. Together, our results indicate that cats previously infected with SARS-CoV-2 can be experimentally reinfected with SARS-CoV-2; however, the levels of virus shed was insuﬃcient for transmission to co-housed naïve
sentinels. We conclude that SARS-CoV-2 infection in cats induces immune responses that provide partial, nonsterilizing immune protection against re-infection.
ARTICLE HISTORY Received 18 January 2021; Revised 9 March 2021; Accepted 10 March 2021
KEYWORDS SARS-CoV-2; COVID-19; re-infection; transmission; cats

Introduction
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) is the causative agent of Coronavirus
Disease 2019 (COVID-19), ﬁrst identiﬁed in Wuhan
China in late 2019 and responsible for the ongoing
global pandemic [1]. SARS-CoV-2 is highly transmissible and capable of causing severe disease in humans.
Furthermore, there have been multiple cases reported
of transmission from COVID-19 patients to animals
including domestic cats, large cats, dogs, ferrets, and
mink in China, South America, the United States
and Europe ([2–9]; summary of US cases: https://www.
aphis.usda.gov/aphis/ourfocus/animalhealth/SA_One_
Health/sars-cov-2-animals-us). Evidence supporting

reverse zoonosis of mink infecting humans has also
been reported [10]. Understanding SARS-CoV-2 susceptibility, transmission and re-infection in companion
animals and livestock species that are frequently in
close proximity with humans is important for assessing
risk and implementing mitigation strategies to stop
virus spread in order to maintain public health as
well as food and economic security [11].
Recently, we and others have demonstrated that
domestic cats are susceptible to SARS-CoV-2 by
experimental infection and can readily transmit the
virus to naïve cats [12–15]. Cats inoculated via natural
routes of exposure can be infected and shed the virus
from nasal, oral and rectal cavities starting from 1 up
to 14 days with peak virus shedding occurring within
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the ﬁrst 7 days after infection [12–15]. Together these
studies show that cats ranging from 4 months up to 8
years of age remain asymptomatic with no signiﬁcant
gross pathological changes, and mild to moderate histological alterations associated mainly with the upper
respiratory tract tissues [12–15]. In contrast, mortality
and severe histological lesions in tissues of the upper
and lower respiratory tract were observed for juvenile
cats younger than 4 months of age infected with
SARS-CoV-2 [13]. Cats also develop virus-speciﬁc
and neutralizing antibody responses to SARS-CoV-2
[7,12–17]. A more detailed understanding of the role
that these immune responses play in protection from
re-exposure to SARS-CoV-2 is imperative.
Here, we present a detailed investigation on SARSCoV-2 re-infection of sub-adult domestic cats at 21
DPC in two independent studies. In the second reinfection study, two sentinel contact cats were introduced at 1 DP2C to determine if transmission to
naïve animals could occur after re-infection. Results
of the clinical course of SARS-CoV-2 re-infection,
viral shedding and transmission in cats previously
infected with SARS-CoV-2 are presented.

Materials and methods
Cells and virus
Vero E6 cells (ATCC® CRL-1586™, American Type Culture Collection, Manassas, VA, USA) were used for virus
propagation and titration. Cells were cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Corning,
New York, NY, USA), supplemented with 5% fetal
bovine serum (FBS, R&D Systems, Minneapolis, MN,
USA) and antibiotics/antimycotics (ThermoFisher
Scientiﬁc, Waltham, MA, USA), and maintained at 37 °
C under a 5% CO2 atmosphere. The SARS-CoV-2
USA-WA1/2020 strain was acquired from BEI Resources
(Manassas, VA, USA) and passaged three times in Vero
E6 cells to establish a stock virus (1 × 106 TCID50/mL)
for inoculation of animals. This stock virus was
sequenced by next generation sequencing (NGS) using
the Illumina MiSeq and its consensus sequence was
found to be homologous to the original USA-WA1/
2020 strain (GenBank accession: MN985325.1). To
determine infectious virus titer, 10-fold serial dilutions
were performed on Vero E6 cells. The presence of cytopathic eﬀects (CPE) after 96 hours incubation was used
to calculate the 50% tissue culture infective dose
(TCID50)/mL using the Spearman-Karber method.
Animals and experimental design
Ethics statement for use of animals
All animal studies and experiments were approved
and performed under the Kansas State University
(KSU) Institutional Biosafety Committee (IBC,
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Protocol #1460) and the Institutional Animal Care
and Use Committee (IACUC, Protocol #4390) in compliance with the Animal Welfare Act. All animal and
laboratory work were performed in biosafety level-3
+ and -3Ag facilities in the Biosecurity Research Institute at KSU in Manhattan, KS, USA.
SARS-CoV-2 re-infection of animals
Two independent re-infection studies were performed
in sub-adult domestic cats 5 or 7 months of age,
respectively. The cats were antibody proﬁle deﬁned/
speciﬁc pathogen free (APD/SPF) animals with no
detectable antibody titers to feline herpesvirus, feline
calicivirus, feline panleukopenia virus, feline coronaviruses, feline immunodeﬁciency virus, Chlamydia
felis and Toxoplasma gondii, and obtained from Marshall BioResources (North Rose, New York, USA).
Animal identiﬁcation numbers and treatment assignments for each study are summarized in Table 1. In
the ﬁrst study, three cats from a previous SARSCoV-2 challenge and transmission study [12], including one principal and two sentinel cats, were re-challenged with SARS-CoV-2 at 21 days post primary
challenge (DPC) and sacriﬁced at 4 days post second
challenge (DP2C). The same dose as used for primary
challenge, namely 2 mL of 106 TCID50 SARS-CoV-2
was administered to each cat both intranasal (0.5 mL
per nostril) and per os (1 mL) simultaneously.
In the second study, a total of six principal cats, two
groups of three, were challenged with SARS-CoV-2
with the same dose and route as detailed in the ﬁrst
study. At 1 DPC, two sentinel contact cats were
added, one per group of challenged cats. Post-mortem
examinations were performed on two principal animals at 4 DPC and one principal animal at 21 DPC.
At 21 DPC, ﬁve cats including the remaining three
principals and the two sentinels were re-challenged
with SARS-CoV-2 using the same dose and route as
in the primary challenge. At 1 DP2C, two new naïve
Table 1. Animals and treatment assignments.
Primary challenge
Cat ID

Treatment

Necropsy

Study 1 (5-month-old domestic cats)
328
Principal
na
272
sentinel (1 DPC)
na
903
sentinel (1 DPC)
na
Study 2 (7-month-old domestic cats)
305
Principal
4 DPC
526
Principal
4 DPC
160
Principal
21 DPC
135
Principal
na
590
Principal
na
247
Principal
na
119
sentinel (1 DPC)
na
127
sentinel (1 DPC)
na
280
na
na
620
na
na

Re-challenge
Treatment

Necropsy

principal (21 DPC)
principal (21 DPC)
principal (21 DPC)

4 DP2C
4 DP2C
4 DP2C

na
na
na
principal (21 DPC)
principal (21 DPC)
principal (21 DPC)
principal (21 DPC)
principal (21 DPC)
sentinel (1 DP2C)
sentinel (1 DP2C)

na
na
na
4 DP2C
4 DP2C
7 DP2C
7 DP2C
14 DP2C
14 DP2C
14 DP2C

Principal: virus inoculated cat; sentinel: naïve contact cat; DPC: days post
primary challenge; DP2C: days post second challenge; na: not
applicable.

Days post primary challenge.
Days post second challenge.
Previously reported, Gaudreault et al. [12].
na: not available/serum not collected; N: nucleocapsid protein; RBD: receptor-binding domain; P: principal infected; S: sentinel introduced during primary infection; +: ELISA positive; -: ELISA negative/below cut-oﬀ; ±: OD close to cut-oﬀ.
c

b

a

<1:20
<1:20
<1:20
<1:20
na
na
na
na
na
na
na
na

na
na

na
na

–
–

na
na

–
–

–
–

na
na

na
na

na
na

na
na

<1:20
<1:20

na
na

na
na
na
na
na
na
na
1:320
na
na
na
na
na
na
1:320
na
na
1:640
1:160c
1:160c
1:160c
1:160
1:160
1:40
1:40
<1:20
1:80
+
+
+
+
+
na
na
na
na
+
+
+
+
+
+
na
+
+

Re-challenged cats
1
328 (P)
1
272 (S)
1
903 (S)
2
135 (P)
2
590 (P)
2
247 (P)
2
160 (P)
2
127 (S)
2
119 (S)
Sentinel contact cats
2
280
2
620

+c
−c
±c
+
+
+
+
−
+

+c
+c
+c
+
+
+
+
+
+

na
+c
+c
+
+
+
+
+
+

+
+
+
+
+
+
na
+
+

na
na
na
na
na
+
na
na
+

na
na
na
na
na
na
na
+
na

na
na
na
na
na
na
na
+
na

1:20c
<1:20c
<1:20c
1:40
1:20
1:40
1:40
<1:20
<1:20

1:160c
1:160c
1:160c
1:320
1:80
1:40
1:80
1:40
1:80

1:80
1:80
1:160
1:160
1:80
1:80
na
1:80
1:320

1:160
1:160
1:80
1:320
1:160
1:160
na
1:40
1:160

1:160
1:80
1:160
1:320
1:160
na
na
na
na

11b
7b
4b
3b
1b

Virus neutralizing antibodies

21a
14a
7a
14b
11b
7b
4b
3b
1b

Anti-N & anti-RBD antibodies

21a
14a
7a
Cat IDs
Study

Table 2. SARS-CoV-2 speciﬁc and neutralizing antibody responses following primary challenge and re-challenge in cats.

na
na
na
na
na
na
na
1:320
na
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sentinel cats were introduced. Two re-challenged animals each were euthanized and post-mortem examinations performed at 4 and 7 DP2C, respectively. The
remaining re-challenged cat and the two sentinels
were euthanized and post-mortem examinations performed at 14 DP2C.
Clinical evaluations and sample collection
Cats were observed daily for clinical signs, as described
previously [12]. Weights of all cats were recorded on
bleed days. Blood and serum were collected from all
primary inoculated and sentinel cats at 0, 1, 3, 4, 7,
14 and 21 DPC, and the re-infected and sentinels at
0, 1, 3, 4, 7, 11 and 14 DP2C via venipuncture of the
cephalic vein under anaesthesia or during terminal
bleeding by cardiac puncture. Nasal, oropharyngeal
and rectal swabs were collected at 0, 1, 3, 4, 5, 7, 10,
14, 18 and 21 DPC, and at 0, 1, 3, 4, 5, 7, 8, 11 and
14 DP2C in 2 mL of DMEM (Corning,) with antibiotics/antimycotic (ThermoFisher). Swabs were vortexed and supernatant aliquoted directly into
cryovials or into RLT buﬀer (Qiagen, Germantown,
MD, USA) and stored at −80 °C until further analysis.
A full post-mortem examination was performed for
each cat and gross changes (if any) were recorded. Tissues were collected either in 10% neutral-buﬀered formalin (Fisher Scientiﬁc, Waltham, MA, USA), or as
fresh tissues which were then frozen at −80 °C. Tissues
were collected from the upper respiratory tract (URT)
and lower respiratory tract (LRT), central nervous system (brain and cerebral spinal ﬂuid [CSF]), gastrointestinal tract (GIT) as well as accessory organs. Lung
lobes were evaluated based on gross pathology and
then bronchoalveolar lavage ﬂuid (BALF) was collected. The lungs were removed in toto including the
trachea. The main bronchi were collected at the level
of the bifurcation and at the entry point into the
lung lobe. Nasal wash and urine were also collected
during post-mortem examination and stored at −80°
C until analysed. Fresh frozen tissue homogenates
were prepared as described previously [12] and the
supernatant retained for RNA extraction and quantitative reverse transcription real-time PCR (RT-qPCR).
RNA extraction and quantitative real-time
reverse transcription PCR (RT-qPCR)
SARS-CoV-2-speciﬁc RNA was detected using a quantitative reverse transcription real-time PCR (RTqPCR) assay as previously described [12]. Brieﬂy, tissue homogenates and swab samples in DMEM,
blood, CSF, BALF, and urine, were mixed with an
equal volume of RLT RNA stabilization/lysis buﬀer
(Qiagen, Germantown, MD, USA), and 200μl of
sample lysate was then used for extraction using a
magnetic bead-based nucleic acid extraction kit
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(Gene-Reach USA, Lexington, MA) on an automated
TacoTM mini nucleic acid extraction system (GeneReach) as described previously [12]. Positive (IDT,
IA, USA; 2019-nCoV_N_Positive Control, diluted
1:100 in RLT) and negative extraction controls were
employed.
Quantiﬁcation of SARS-CoV-2 RNA was performed as previously described [12] using the N2
SARS-CoV-2 primer and probe set in a RT-qPCR protocol established by the CDC for the detection of
SARS-CoV-2 nucleocapsid protein (N)-speciﬁc RNA
[18]. A 10-point standard curve of quantitated viral
RNA (USA-WA1/2020 isolate) was used to quantify
RNA copy number. A positive Ct cut-oﬀ of 40 cycles
was used and any signal after the 40 cycle threshold
was considered as non-speciﬁc or not signiﬁcant.
Each sample was run in duplicate reactions and only
samples with 2 out of 2 positive RT-qPCR reactions
are presented. Samples with 1 of 2 RT-qPCR positive
reactions were treated as suspect and indicated by an
asterisk in the presented ﬁgures. Data are shown as
the mean of the calculated N gene copy number per
mL of liquid sample or per mg of a 20% tissue
homogenate.

Virus isolation
Select swab and tissue homogenate samples from rechallenged cats were tested for viable virus by culture on Vero E6 cells. Virus isolation was performed
by culturing 400 µL of ﬁltered sample on Vero E6
cells and monitoring for CPE for up to 5 days
post inoculation. Based on our test results of
samples from primary infected cats, virus isolation
was only performed on samples with ≥106 RNA
copy number per mL, as this was our approximate
limit of detection (LOD) for viable virus using this
method.

Histopathology
Tissue samples from the nasal cavity [rostral, middle
and deep turbinates following decalciﬁcation with
Immunocal™ Decalciﬁer [StatLab, McKinney, TX]
for 4–7 days at room temperature], trachea, and
lungs as well as various other extrapulmonary tissues (liver, spleen, kidneys, heart, pancreas, gastrointestinal tract [stomach, small intestine including
Peyer’s patches and colon], cerebrum [including
olfactory bulb], tonsils and numerous lymph
nodes) were routinely processed and embedded in
paraﬃn. Four-micron tissue sections were stained
with haematoxylin and eosin following standard
procedures. Several independent veterinary pathologists (blinded to the treatment groups) examined
the slides.
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SARS-CoV-2-speciﬁc RNAscope® in situ
hybridization (RNAscope® ISH)
RNAscope® ISH was performed as previously
described [12] using an anti-sense probe targeting
the spike protein gene (S; nucleotide sequence:
21,563–25,384) of SARS-CoV-2, USA-WA1/2020 isolate (GenBank accession number MN985325.1) which
was designed by Advanced Cell Diagnostics ([ACD],
Newark, CA, USA) and used as previously described
[19]. Four-micron sections of formalin-ﬁxed
paraﬃn-embedded tissues were subjected to in situ
hybridization. Lung sections from a SARS-CoV-2infected hamster were used as positive assay controls.
SARS-CoV-2-speciﬁc immunohistochemistry
(IHC)
IHC was performed as previously described [12] on
four-micron sections of formalin-ﬁxed paraﬃnembedded tissue mounted on positively charged
Superfrost® Plus slides and subjected to IHC using a
SARS-CoV-2-speciﬁc anti-nucleocapsid rabbit polyclonal antibody (3A, developed by our laboratory)
with the method previously described [19]. Lung sections from a SARS-CoV-2-infected hamster were used
as positive assay controls.
Virus neutralizing antibodies
Virus neutralizing antibodies in sera were determined
using microneutralization assay as previously
described [12]. Brieﬂy, heat inactivated serum samples
were subjected to two-fold serial dilutions starting at
1:20, and tested in duplicate. Then, 100 TCID50 of
SARS-CoV-2 virus in DMEM culture media was
added 1:1 to the sera dilutions and incubated for 1 h
at 37 °C, then cultured on Vero E6 cells in 96-well
plates. The corresponding SARS-CoV-2-negative cat
sera, virus only and media only controls were also
included in the assay. The neutralizing antibody titer
was recorded as the highest serum dilution at which
at least 50% of wells showed virus neutralization
based on the appearance of CPE observed under a
microscope at 72 h post infection.
Detection of SARS-CoV-2 antibodies by indirect
ELISA
To detect SARS-CoV-2 antibodies in sera, indirect
ELISAs were performed with the recombinant viral
proteins, nucleoprotein (N) and the receptor-binding
domain (RBD), as previously described [12]. Brieﬂy,
wells were coated with 100 ng of the respective recombinant protein and serum samples were pre-diluted
1:400 for the assay. The cut-oﬀ for a sample being
called positive was determined as follows: Average
OD of negative serum + 3× standard deviation. Every
read out above this cut-oﬀ was considered positive.
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Results
Primary infected cats shed SARS-CoV-2, develop
histologic lesions in the respiratory tract, and
seroconvert while remaining clinically
asymptomatic
A similar study design was used for the primary cat
infections as in our previous study evaluating primary
infection and transmission in cats [12]; it consisted of
six principal cats inoculated with SARS-CoV-2 and
two sentinel contact cats introduced at 1 DPC (Figure
1). At 4 and 21 DPC, two and one of the principal
infected cats were necropsied, respectively, to characterize primary infection and histological changes at
these DPC, prior to re-infection of the ﬁve remaining
animals at 21 DPC. Similar to our previous study
[12], primary SARS-CoV-2 challenged cats shed virus
from nasal, oral and rectal cavities and eﬃciently transmitted the virus to the naïve sentinels (Figure 2(a–c)).
Viral RNA was found in multiple tissues of the two
principal infected cats euthanized at 4 DPC, including
the URT, LRT, GIT, lymphatic organs, heart and olfactory bulb (Figure 3). Histologic lesions were restricted
to the upper respiratory tract and the bronchial tree as
previously described [12]. Within the nasal cavity,
there was evidence of neutrophilic rhinitis of variable
intensity with numerous neutrophils inﬁltrating the
lamina propria, transmigrating through the lining epithelium, and accumulating in the lumen along with
cellular debris (Figure 4). The respiratory epithelium
showed occasional sloughing (erosion) and attenuation. Seromucinous nasal glands were largely spared
of histologic changes, with only rare glands within
inﬂamed areas containing few luminal neutrophils or
cell debris. SARS-CoV-2 antigen and viral RNA were
detected within individual or clusters of squamous
(rostral turbinates) and respiratory epithelial cells

(intermediate and deep turbinates) via IHC and ISH.
Even though the olfactory neuroepithelium was histologically unremarkable, viral antigen and RNA were
segmentally detected (Figure 4). Lesions in the trachea
and bronchial tree were mild, characterized by multifocal lymphohistiocytic and neutrophilic tracheobronchoadenitis with necrosis of the glandular epithelium and
intralesional SARS-CoV-2 antigen and RNA as previously described (Figure 4; 12). At 21 DPC, viral shedding had subsided in both principal and contact
primary infected animals, except for a single RNA
positive oropharyngeal swab detected from one of
the principal infected cats (Figure 2(b)). Limited viral
RNA was detected in tissues of the URT, lymphatic
organs and olfactory bulb, but not in the nasal wash,
BALF, lung or digestive tract tissues of the principal
infected cat euthanized at 21 DPC (Figure 3); virus isolation was not performed on these speciﬁc samples
since RNA copy number was below the limit of detection for our virus isolation assay. All cats including
principal and sentinel primary infected animals had
detectable virus-speciﬁc and virus neutralizing antibodies by 21 DPC/0 DP2C (Table 2). At this time
point, the intense neutrophilic rhinitis noted at 4
DPC was replaced by multifocal lymphoid aggregates
in the lamina propria with only rare and localized
areas of minimal neutrophilic inﬂammation. The respiratory mucosa and olfactory neuroepithelium were
unremarkable and no viral antigen or RNA were
detected within the nasal cavity at this timepoint
(Figure 4). In the trachea and bronchi, there was no
evidence of damage to tracheal and bronchial glands
as noted at 4 DPC, with no viral antigen or RNA
detected. Tracheal glands were only separated by
mild numbers of lymphocytes and plasma cells, and
peribronchial lymphoid aggregates were noted along
the bronchial tree (Figure 4). Finally, no lesions were

Figure 1. Re-infection study design. (a) In each of 2 studies, 6 cats were inoculated with SARS-CoV-2 and 2 sentinel contact cats
were introduced at 1 day post primary challenge (DPC). Necropsy was performed on principal infected cats at 4, 7 and 21 DPC. (b)
At 21 DPC, cats were re-challenged with SARS-CoV-2 at the same dose as used for primary challenge, and 2 sentinels introduced at
day 1 post second challenge (DP2C). Necropsy of principal re-infected cats were performed at 4, 7 and 14 DP2C, and of the sentinels at 14 PD2C.
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Figure 2. Viral shedding from SARS-CoV-2 infected and re-infected cats. RT-qPCR was performed on nasal (a), oropharyngeal (b)
and rectal (c) swabs collected from cats at the indicated days following primary challenge (DPC) and re-challenge (DP2C) from the
second re-infection study. Results represent all cats that were swabbed and tested at 0, 1, 3, 5, 7, 10, 14, 18 and 21 DPC, and at 0, 1,
3, 5, 7, 8, 11 and 14 DP2C. Results at 4 DPC and 4 DP2C are representative of only the 2 necropsied cats that were swabbed and
tested on these days. (d) Nasal, oropharyngeal and rectal swabs collected from the 3 re-challenged cats from the ﬁrst re-infection
study. Mean and standard deviation of viral RNA copy number (CN) per mL based on the nucleocapsid gene are shown. Asterisks
(*) indicate samples with 1 out of 2 of the RT-qPCR reactions below the limit of detection (LOD), indicated by the dotted line.

identiﬁed in extrapulmonary tissues other than lymphoid hyperplasia within lymphoid organs.
Re-infection of cats with SARS-CoV-2 leads to
asymptomatic and limited viral shedding
At 21 DPC/0 DP2C, three cats from the ﬁrst study and
ﬁve cats of the second study were re-challenged with
SARS-CoV-2 (Figure 1). In the ﬁrst study, viral shedding
was detected from nasal swabs at 1 DP2C and from rectal swabs at 1–4 DP2C, but not from oropharyngeal
swabs of the three re-challenged cats (Figure 2(d)). Rechallenged cats from the second study shed viral RNA
intermittently from the nasal cavity at 1 through 4
DP2C and similarly from the oropharyngeal cavity at
1 through 11 DP2C; however, no viral RNA was detected
from rectal swabs after re-challenge in study 2 (Figure 2
(a–c)). No viable virus was detected in the swabs of reinfected cats from either study.
In addition, viral RNA was detected in the nasal
wash, URT and GIT tissues of re-infected cats euthanized at 4 and 7 DP2C (Figure 3(a,d,f)). Limited
viral RNA was detected in the LRT of some animals
and some LRT tissues of cats euthanized after re-infection at 4 and 7 DP2C, including the bronchi and three

of the seven lung sections collected (Figure 3(e)). Viral
RNA was also found in the lymphatic tissues, heart
and olfactory bulb of the re-infected cats at 4 and 7
DP2C, and the kidney of one animal at 4 DP2C, at
similar levels as detected in the cats during primary
infection (Figure 3). CSF from one of the re-challenged cats euthanized at 4 DP2C was also positive
(Figure 3(c)). By 14 DP2C, viral RNA was only
detected in the tonsil of the remaining principal rechallenged cat. No viral RNA was detected from the
blood of primary SARS-CoV-2 challenged or re-challenged cats (data not shown).
No signiﬁcant clinical symptoms or weight changes
were observed for any of the primary SARS-CoV-2
challenged or re-challenged cats during the course of
these studies. On the day of re-challenge, all cats had
virus neutralizing antibodies with titers ranging from
1:40 to 1:320 (Table 2). A statistically signiﬁcant
increase in neutralizing antibody titers was observed
following re-infection at 7 DP2C, suggestive of an anamnestic immune response after re-infection with
SARS-CoV-2 (Table 2 and Figure 5).
Histologic changes within the upper and lower respiratory tracts, as well as extrapulmonary tissues were
evaluated in re-infected cats. While there was evidence
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Figure 3. SARS-CoV-2 RNA detected in various tissues from infected and re-infected cats. RT-qPCR was used to detect the presence
of SARS-CoV-2 in various tissues of cats euthanized at the indicated days after primary challenge (DPC) and re-challenge (DP2C).
Viral RNA copy number (CN) per mL (a–c) or mg (d–h) based on the nucleocapsid gene are plotted for individual animals. Coloured
symbols corresponding to cat ID numbers, day of necropsy and study are indicated in the ﬁgure key. Asterisks (*) indicate samples
with 1 out of 2 of the RT-qPCR reactions below the limit of detection (LOD) which is, indicated by the dotted line.

of minimal to mild neutrophilic rhinitis (particularly
on rostral and intermediate turbinates) at 4 DP2C,
this was not as intense as that observed at 4 DPC. In
all re-infected cats (4, 7 and 14 DP2C), multiple lymphoid aggregates were noted in the nasal passages
similar to those noted at 21 DPC (Figure 6). No alterations within the respiratory mucosa (other than
occasional transmigrating lymphocytes) and olfactory
neuroepithelium were noted in nearly all re-infected
animals. In a single cat from the second study (#5904 DP2C), few neutrophils inﬁltrated a localized area
of the olfactory neuroepithelium. No viral antigen or
RNA were detected in the nasal cavity at any timepoint
following re-infection (Figure 6). In the trachea and
bronchi of re-infected cats, there was no evidence of
tracheobronchoadentitis as noted at 4 DPC, and no
viral antigen or RNA detected. Mild numbers of lymphocytes and plasma cells inﬁltrated tracheal and
bronchial glands, and frequently formed lymphoid
aggregates along the bronchial tree, interpreted as
hyperplastic bronchial-associated lymphoid tissue
(BALT, Figure 6).

While no signiﬁcant histologic alterations were evident in the pulmonary parenchyma of primary
infected cats and most of the re-infected cats (5/8), a
localized area of reparative alveolitis was identiﬁed
in a single bronchopulmonary segment in re-infected
cats from the second study: #590 (4 DP2C), #119 (7
DP2C) and #127 (14 DP2C). The aﬀected area was
characterized by early (#590) to ﬂorid (#119 and
#127) alveolar type 2 cell hyperplasia with few inﬁltrating mononuclear cells (lymphocytes and histiocytes)
and small amounts of sloughed cell debris. No
SARS-CoV-2 antigen or RNA were detected in the
aﬀected area or elsewhere in the pulmonary parenchyma (data not shown). No histologic changes in extrapulmonary organs were observed other than lymphoid
hyperplasia within lymphoid organs.
Re-infected cats do not transmit SARS-CoV-2 to
sentinels
In the second re-infection study, two sentinel SARSCoV-2 antibody-negative contact cats were
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Figure 4. (a) Histologic lesions in the respiratory tract of primary infected cats. Mock-infected (A–C), 4 (D–F), and 21 days postchallenge (DPC; G–I) with SARS-CoV-2. At 4 DPC, intense neutrophilic rhinitis with luminal exudate (D, arrowhead and arrow,
respectively) and lymphohistiocytic and neutrophilic tracheobronchoadenitis with necrosis and obliteration of seromucinous
glands (E and F, arrows) were characteristic. At 21 DPC, histologic changes were limited to lymphoid aggregates in the lamina
propria of the nasal turbinates (G), trachea (H) and bronchi (I). H&E, 200× total magniﬁcation. Bar = 100 μm. (b). SARS-CoV-2 distribution as determined by in situ hybridization in the respiratory tract of primary infected cats. Mock-infected (A–C), 4 (D–F), and
21 DPC (G–I) with SARS-CoV-2. At 4DPC, SARS-CoV-2 RNA was detected and localized within the nasal respiratory epithelium,
olfactory neuroepithelium (D) and tracheobronchial glands in trachea and bronchi (E and F). At 21 DPC, no viral RNA was detected
in the respiratory tract (G–I). Fast Red, 200× total magniﬁcation. Bar = 100 μm. (c). SARS-CoV-2 distribution as determined by
immunohistochemistry in the respiratory tract of primary infected cats. Mock-infected (A–C), 4 (D–F), and 21 DPC (G–I) with
SARS-CoV-2. At 4DPC, SARS-CoV-2 antigen was present in the nasal respiratory epithelium, olfactory neuroepithelium (D) and tracheobronchial glands in trachea and bronchi (E and F), co-localizing with viral RNA. At 21 DPC, no viral antigen was detected in the
respiratory tract (G–I). Fast Red, 200× total magniﬁcation. Bar = 100 μm.

introduced and co-mingled with the re-challenged
cats at 1 DP2C in order to determine if virus transmission occurrs following re-infection. The sentinels
introduced after re-infection had temperatures slightly
above 39°C at 2–4 DP2C but were otherwise within
normal range and remained asymptomatic up to 14
DP2C (supplemental ﬁgure 1). No viral shedding
from nasal, oropharyngeal and rectal cavities was
observed in these animals (Figure 2(a–c)) and no
viral RNA was detected in tissues from either of the
sentinel cats examined at 14 DP2C (Figure 3). Furthermore, the naïve sentinel cats co-housed with the reinfected cats for 13 days after re-challenge did not seroconvert (Table 2). Histologic evaluation of the nasal
cavity identiﬁed multiple lymphoid aggregates similar
to those noted in cats at 21 DPC and following reinfection with SARS-CoV-2. Minimal inﬁltrating

lymphocytes and plasma cells along with sporadic
lymphoid aggregates were noted in the submucosa
along the bronchial tree, with no histologic changes
in the pulmonary parenchyma. Viral antigen and
RNA were not detected in tissues from sentinel cats.

Discussion
Knowledge of SARS-CoV-2 viral evolution, immunology and the longevity of immune protection
against re-infection is still limited. Cases of SARSCoV-2 re-infections in humans have been recently
reported [20–26]. Although the reported cases are
relatively few, the true percentage and frequency of
SARS-CoV-2 re-infections remain unclear. Furthermore, the outcome of a re-infection in terms of clinical
disease and transmission is still not clearly
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Figure 5. Virus neutralizing antibody responses in primary
infected and re-challenged cats. Statistical analysis of virus
neutralizing antibody titers were determined by multiple ttest using the Holm-Sidak method, with alpha=5.000%. Only
data for a single re-infected cat was available at 14 DP2C
therefore signiﬁcance could not be calculated. Statistical signiﬁcance is indicated by: *<0.05; **<0.005; ***<0.0005; DPC
= days post primary challenge; DP2C = days post second
challenge

understood. While identifying and characterizing reinfection in humans naturally infected or vaccinated
and re-exposed to SARS-CoV-2 remains important,
studies using susceptible animal models allow for
more systematic, in-depth investigations which can
provide insight into SARS-CoV-2 re-infections in
humans. Therefore, we investigated experimental reinfection in domestic cats as well as transmission following re-infection with SARS-CoV-2.
Based on our previous results from primary SARSCoV-2 infection in cats [12] and BSL-3Ag room scheduling constraints, cats were re-challenged at 21 DPC
for these studies. Our results indicate that a primary
SARS-CoV-2 infection was mostly resolved within
21 DPC. At 21 DPC, viral RNA shedding had subsided in the nasal and rectal cavities (Figure 2), no
viral RNA or antigen were detected in the upper
and lower respiratory tract with the exception of
nasal turbinate, and nasopharynx homogenates
(Figures 3 and 4). In addition, the histologic changes
seen at early stages of infection (i.e. 4 and 7 DPC),
characterized by intense neutrophilic rhinitis and tracheobronchoadenitis with necrosis of seromucinous
glands of the trachea and bronchi, had completely
resolved with only occasional lymphoid aggregates
present along segmental bronchi. Following re-challenge, our results indicate that cats were at least partially protected from re-infection. All cats had
circulating neutralizing antibodies at the time of rechallenge (Table 2), and viral RNA was detected
from fewer tissues and at lower levels in the reinfected cats compared to primary infected cats
examined at the same day after virus challenge (12;
Figures 2 and 3). In our ﬁrst re-infection study,
viral RNA was detected in nasal washes, the URT
and some LRT tissues of the three re-infected cats

examined at 4 DP2C, suggesting that limited infection
mainly in the URT might occur after SARS-CoV-2 rechallenge. Interestingly, in our second study, nasal
washes, URT and GIT tissues of the two cats examined at 7 DP2C but not at 4 DP2C were RNA positive;
this might suggest that the viral RNA detected in the
URT and GIT may not be residual viral RNA from
the SARS-CoV-2 challenge but replicating virus following re-challenge. Limited viral RNA shedding
was also detected from nasal and rectal cavities up
to 4 DP2C and oropharyngeal swabs up to 11
DP2C. The diﬀerence in RNA presence at 4 DP2C
between the two studies could be related to the age
of the cats (5 versus 7 months) and/or variation of
responses among individual animals. Nonetheless,
no viable virus was isolated from the swab samples
of the re-infected cats, and the two sentinel contact
cats co-housed with the re-challenged cats for 13
days remained SARS-CoV-2 negative and did not seroconvert. Therefore, re-challenged animals either did
not shed viable virus or shed virus at insuﬃcient
levels for transmission to sentinels.
Interestingly, re-infected cats did not develop
intense neutrophilic rhinitis or acute inﬂammation
and necrosis targeting tracheobronchial glands when
compared to primary infected cats at 4 DPC, and no
viral antigen or RNA was detected within respiratory
tract tissues following re-infection. The lymphoid
aggregates frequently noted within the nasal passages
and throughout the bronchial tree of re-infected cats
resemble hyperplastic nasal and bronchi-associated
lymphoid tissue (NALT and BALT), most likely a
non-speciﬁc change following exposure to airborne
pathogens. Whether this change represents a speciﬁc
host immune response that either remained following
the initial exposure to SARS-CoV-2 and expanded following re-exposure is unclear, since similar lymphoid
clusters, albeit at lower frequency, were noted in the
sentinel cats and in one of the mock-infected cats
included in our ﬁrst infection study [12]. A larger
sample size and/or additional animals necropsied at
25, 28 or 35 days after primary challenge would be
necessary in order to conﬁdently determine the frequency and distribution of this histopathological
ﬁnding. However, due to BSL-3Ag room and housing
constraints, including additional animals for these
studies was not possible.
An additional and unexpected histologic lesion
when compared to primary infected cats corresponded to the focal reparative alveolitis in three of
the re-challenged cats. Unfortunately, the association
of this histologic change with SARS-CoV-2 re-infection cannot be unequivocally conﬁrmed. However,
its association with SARS-CoV-2 infection is unlikely
due to several reasons: (1) SARS-CoV-2 does not
show a speciﬁc tropism for feline bronchial, bronchiolar or alveolar epithelial cells [12]; (2) no viral antigen
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Figure 6. (a) Histologic lesions in the respiratory tract of re-challenged cats. 4 (A–C), 7 (D–F), and 14 days post second challenge
(DP2C; G–I) with SARS-CoV-2. At all time points, variable lymphoid aggregates expanded the lamina propria of the nasal turbinates
(A, D, G), trachea (B, E, H) and bronchi (C, F, I). No disruption of tracheobronchial glands was noted. H&E, 200× total magniﬁcation.
Bar = 100 μm. (b) SARS-CoV-2 distribution as determined by in situ hybridization in the respiratory tract of re-challenged cats. 4
(A–C), 7 (D–F), and 14 DP2C (G–I) with SARS-CoV-2. No viral RNA was detected in the nasal cavity (A, D, G), trachea (B, E, H) or
bronchi (C, F, I) at any time point. Fast Red, 200× total magniﬁcation. Bar = 100 μm. (c) SARS-CoV-2 distribution as determined by
immunohistochemistry in the respiratory tract of re-challenged cats. 4 (A–C), 7 (D–F), and 14 DP2C (G–I) with SARS-CoV-2. No viral
antigen was detected in the nasal cavity (A, D, G), trachea (B, E, H) or bronchi (C, F, I) at any time point. Fast Red, 200× total
magniﬁcation. Bar = 100 μm.

(by IHC) or viral RNA (via ISH and RT-qPCR) were
detected within these lesions; (3) histologic changes
suggestive of alveolar injury and repair were regional
and not generalized and were not associated with
clinical signs of disease; (4) the alveolar lesions were
not present in all re-challenged cats. Other possible
causes such as immune-mediated responses or inhaled
antigens from the inoculum or environment should be
considered. Additional experiments with a larger
sample size are warranted to further investigate the
mechanisms of immune protection from SARS-CoV2 and the development of pulmonary immunity in
cats. Taken together, these results indicate that experimental re-infection of cats with SARS-CoV-2 results
in partial protection from re-infection with limited
infection primarily of the URT and GIT that was
resolved by 14 DP2C; regardless, re-challenged animals either did not shed viable virus or shed virus at
insuﬃcient levels for eﬃcient transmission to
sentinels.

Other SARS-CoV-2 re-infection studies in cats, ferrets and rhesus macaques also showed at least partial
to full protection from re-exposure at 4 weeks after
primary challenge [27–29]. In a study by BoscoLauth and colleagues [15], three adult cats 5–8 years
of age were experimentally infected with SARS-CoV2 and re-challenged 28 days later. In that study, no
nasal or oral shedding of virus was observed during
the 7 days after re-challenge and it was concluded
that the animals were resistant to SARS-CoV-2 reinfection [15]. In our studies, we also did not detect
infectious virus but did detect viral RNA shedding.
Similar to Bosco-Lauth et al., we also observed a
marked increase in neutralizing antibodies following
SARS-CoV-2 re-challenge, suggestive of an anamnestic immune response. Similar results to ours were
obtained in re-infection studies with non-human primates (NHPs) by two diﬀerent groups [28,29]. After
the initial SARS-CoV-2 clearance, animals were rechallenged with SARS-CoV-2 and showed signiﬁcant
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reductions in viral loads in bronchoalveolar lavage and
nasal mucosa when compared to the primary infection
[28,29]. Anamnestic immune responses after re-challenge suggested that protection was mediated by
immunologic control. The authors concluded that
SARS-CoV-2 infection in rhesus macaques led to
SARS-CoV-2 speciﬁc immune responses and provided
protection against re-challenge. The residual levels of
subgenomic mRNA in nasal swabs and the anamnestic
immune response after SARS-CoV-2 re-challenge
suggest that protection was mediated by immunologic
control but was not sterilizing [28]. While these
studies indicate that SARS-CoV-2 infection induces
immune responses that provide at least some protection against re-infection in the short-term, the longevity of immune protection and the extent of crossprotection against divergent SARS-CoV-2 isolates
that recently emerged, remain unclear.
Some insight into the longevity of immune
responses and protection from re-infections might
be derived from studies on similar coronaviruses.
Studies on recovered patients infected with Severe
Acute Respiratory Syndrome coronavirus (SARSCoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) indicate that virus-speciﬁc and
neutralizing antibodies can persist for up to 2–3
years before signiﬁcantly declining; still, protection
against re-infection in such seropositive individuals
is not known [30–36]. MERS-CoV re-infections in seropositive camels has been shown to occur [37,38]. A
35 year-long study investigating re-infections in individuals with seasonal human coronaviruses that typically result in minor disease found that re-infections
occurred frequently around a year after the previous
infection, indicating immunity is rather short-lived
[39]. Further studies are needed to understand the
long-term kinetics of immune responses to SARSCoV-2 and how these responses relate to protection
from re-infection; and in cases of only partial protection, the risk of transmission and developing clinical
disease. This work is also critical for determining the
risk of companion animals as reservoirs for perpetuating the spread of SARS-CoV-2 and may also serve as a
model to study SARS-CoV-2 immunity and re-infection in humans.

Conclusions
Here, we demonstrate that experimental SARS-CoV-2
infection in cats induces a protective immune
response providing partial, non-sterilizing immune
protection from re-infection. Furthermore, we show
that re-infected cats did not shed virus at suﬃcient
levels to infect co-housed, naïve animals. Future
studies are aimed at understanding the longevity of
immune protection against SARS-CoV-2. Nonetheless, these results suggest that immunological

approaches to prevent and potentially treat SARSCoV-2 are possible.
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